Skip to main content

CareDx Inc

For the period ended Mar 31, 2025. Filed Apr 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Apr 30, 2025

CDNA$80.77-4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

Three Months Ended March 31,
20252024
Revenue:
Testing services revenue$61,921$53,837
Product revenue10,8108,594
Patient and digital solutions revenue11,9549,618
Total revenue84,68572,049
Operating expenses:
Cost of testing services15,11313,632
Cost of product5,5865,344
Cost of patient and digital solutions7,7166,958
Research and development18,52418,711
Sales and marketing22,99119,830
General and administrative22,76930,140
Litigation settlement expense5,360—
Total operating expenses98,05994,615
Loss from operations(13,374)(22,566)
Other income:
Interest income, net2,7842,885
Other income (expense), net295(290)
Total other income3,0792,595
Loss before income taxes(10,295)(19,971)
Income tax (expense) benefit(58)83
Net loss$(10,353)$(19,888)
Net loss per share (Note 3):
Basic$(0.19)$(0.38)
Diluted$(0.19)$(0.38)
Weighted-average shares used to compute net loss per share:
Basic55,262,45951,692,358
Diluted55,262,45951,692,358
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.